BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 3527304)

  • 1. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
    Santen RJ
    Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
    Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
    J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
    Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
    J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
    Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
    Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
    Friedrichs K; Jänicke F
    Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W; Santen RJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors: new endocrine treatment of breast cancer.
    Brueggemeier RW
    Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
    Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
    Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
    Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
    Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogen treatment of breast cancer: an overview.
    Pearson OH; Manni A; Arafah BM
    Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
    Samojlik E; Santen RJ; Kirschner MA; Ertel NH
    Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of breast cancer.
    Cohen IA; Keller JH; Abate MA
    Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors in breast cancer therapy.
    Brueggemeier RW
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
    Lønning PE; Geisler J; Johannessen DC; Ekse D
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
    Morris KT; Toth-Fejel S; Schmidt J; Fletcher WS; Pommier RF
    Surgery; 2001 Dec; 130(6):947-53. PubMed ID: 11742322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
    Santner SJ; Feil PD; Santen RJ
    J Clin Endocrinol Metab; 1984 Jul; 59(1):29-33. PubMed ID: 6725522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of aromatase activity in human breast cancer.
    Miller WR; Hawkins RA; Forrest AP
    Cancer Res; 1982 Aug; 42(8 Suppl):3365s-3368s. PubMed ID: 7083201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.